Probiotics Manufacturing
Private label and custom probiotic supplement manufacturing through our European laboratory network — strain-matched, stability-tested, and delivered ready to sell.
TechLabs Europe helps supplement brands develop and manufacture probiotic products through a network of specialised European laboratories.
We coordinate the different stages of product development — from strain selection and CFU strategy to delivery format, manufacturing, packaging and regulatory requirements — according to the needs of each project and target market.
Whether you are developing a new probiotic supplement or expanding an existing product range, we help identify the most suitable manufacturing solution for your brand.
Different brands require different levels of development. We assess both routes according to the objectives of each project.
For projects where speed to market is a priority, existing formulations may provide a more efficient route to launch. We can assess suitable ready-developed probiotic solutions that can be adapted to your brand and packaging.
For brands requiring greater differentiation, TechLabs Europe can coordinate the development of a customised formulation across variables including strain selection, CFU dosage, delivery format and serving configuration.
Vegetable capsules, delayed-release / enteric-coated options, room-temperature stable or refrigerated strains.
Available in our networkPowder-to-stick format, higher CFU loads per serving, convenient for travel and dosing flexibility.
Available in our networkBulk or single-serve, unflavoured or flavoured, suitable for blending with prebiotics or functional actives.
Assessed per projectProbiotic formulation is a chain of interdependent choices where getting one variable wrong — strain, CFU guarantee point, or delivery technology — can undermine real-world efficacy, regardless of what the label states.
Single-strain formulations (e.g. Lactobacillus rhamnosus GG) allow clear, strain-specific positioning. Multi-strain blends (often 5–10+ strains) suit broader positioning but require more complex stability testing.
The single most consequential technical decision is the CFU guarantee point: CFU at manufacture will have degraded by the time the consumer opens the bottle, unless production is overfilled to guarantee the labelled count through expiry — our default approach.
Specific strain, CFU count, format and commercial conditions are assessed individually for each project.
This is an indicative example. Final strain, CFU count, format and packaging are assessed project by project according to formulation requirements and manufacturing capabilities.
There is no single ideal probiotic product for every brand. Strain, CFU strategy, format and positioning depend on the target consumer, sales channel and market.
Strain selection and CFU guarantee point are assessed according to positioning, stability requirements and cost targets.
We help determine whether the concept is better suited to a capsule, sachet or powder format.
Packaging is selected according to moisture sensitivity, dosage, stability requirements and intended sales channel.
The target country or countries are considered during development because health claim rules can differ between markets.
We define the product concept, target market, strain focus, format and commercial requirements.
The project is matched with the European laboratory best suited to its technical and format requirements.
We assess an existing private label solution or coordinate a custom formulation together with format and packaging definition.
Production is coordinated with the selected laboratory. Regulatory alignment and documentation are addressed before final delivery.
Probiotic supplements marketed in Europe must comply with the applicable European framework as well as relevant national requirements.
The EFSA has never approved a generic health claim for the term “probiotic” under Regulation (EC) 1924/2006 — meaning the word can carry legal risk if used as an implied health claim in several EU member states. Many established EU brands avoid “probiotic” on-pack and use “live cultures” or name the specific strain instead.
Certain probiotic strains or unconventional sources may also fall under EU Novel Food law (Regulation (EU) 2015/2283), assessed for every strain and formulation.
Our regulatory team reviews all label copy and marketing language before production to manage claim-language risk per target market.
Access specialised supplement manufacturing capabilities through a network of certified European laboratories.
Probiotic-specific health claim restrictions handled as standard, not as an add-on.
Choose between existing solutions for faster market entry or fully customised formulations.
Production overfilled to compensate for die-off, so the labelled count holds through the best-before date.
Labelling, documentation and market-specific requirements addressed as part of the project.
Structured to match first-SKU brands and established ranges alike.
Whether you already have a detailed formulation or only an initial product concept, we can assess the most appropriate route to manufacturing.
TechLabs Europe coordinates private label and custom supplement manufacturing through a network of specialised European laboratories. The manufacturing partner is selected according to the formulation, format, quantities, packaging and destination market of each project.
Yes — this is our default formulation approach. Production is overfilled to compensate for the natural CFU die-off curve, so the guaranteed count on the label holds through the best-before date, not only on the day of manufacture.
It depends on the strain. Spore-forming strains (e.g. certain Bacillus species) are typically shelf-stable at room temperature; other strains require cold-chain storage to preserve viability.
Assessed on a project basis. Gummy manufacturing involves heat and moisture that can compromise live cultures — spore-forming strains or specific production techniques are typically required.
Yes. Our regulatory support covers Novel Food assessment, EU health claim review (including the label-language risk specific to the word “probiotic”), mandatory EU label elements, and multi-language labelling for pan-EU distribution.
MOQ depends on strain complexity, format and packaging specification. Structured to be accessible for emerging brands while supporting scalability for established ranges.
Catalogue formulations: 3–4 weeks standard lead time. Custom strain or blend development adds 2–3 additional weeks for sampling, stability testing and approval.
Whether you need a private label solution, a custom formulation or a differentiated delivery format, TechLabs Europe can identify and coordinate the European manufacturing solution best suited to your project.
